Matthew Reynolds to Ezetimibe
This is a "connection" page, showing publications Matthew Reynolds has written about Ezetimibe.
Connection Strength
0.453
-
Cannon CP, Khan I, Klimchak AC, Sanchez RJ, Sasiela WJ, Massaro JM, D'Agostino RB, Reynolds MR. Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. Am Heart J. 2019 10; 216:30-41.
Score: 0.158
-
Cannon CP, Sanchez RJ, Klimchak AC, Khan I, Sasiela WJ, Reynolds MR, Rosenson RS. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease. Am J Cardiol. 2019 04 15; 123(8):1202-1207.
Score: 0.154
-
Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017 09 01; 2(9):959-966.
Score: 0.140